Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex; IHC (Histoglob) in the Management of Chronic Urticaria: A Prospective, Multicenter, Observational Study.
Bharat Serums and Vaccines Limited
600 participants
Dec 31, 2025
OBSERVATIONAL
Conditions
Summary
This is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria in India.
Eligibility
Inclusion Criteria4
- Male or female patients aged ≥13 years.
- Able and willing to provide written informed consent (or assent where applicable).
- Diagnosed with chronic urticaria with UAS7 prior to enrollment already on first line of treatment for Chronic Urticaria
- Prescribed Histoglob injections for the first time at the discretion of treating physician as part of routine car
Exclusion Criteria6
- Known allergy or hypersensitivity to Histoglob or human immunoglobulin product.
- Patients with acute allergic attack
- Pregnant or lactating women.
- History of malignancy or any condition requiring immunosuppressive therapy other than study indication.
- Participation in any other clinical study.
- Any other condition or circumstance that, in the opinion of the study physician, makes the patient unsuitable for study participation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Histaglobulin prefilled syringe is administered subcutaneously as a single 1mL dose.
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07680413